CTOs on the Move

Triumvira

www.triumvira.com

 
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Donna Rill
Chief Technology Officer Profile

Funding

Triumvira raised $55M on 08/27/2020

Similar Companies

Advanced MRI Consulting

Advanced MRI Consulting is a Evergreen Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humanetics

Humanetics Corp. is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

StemoniX

StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity.

Saltwhistle Technology

Saltwhistle Technology is a Chester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.